Drug intelligence / Profile preview

BI 414

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 414 is a potent, orally available small molecule antagonist of the melanin-concentrating hormone receptor 1 (MCHR1). It was developed by Boehringer Ingelheim as part of their MCHR1 antagonist program targeting obesity. The compound belongs to the biphenylacetamide chemical class and was optimized for improved potency, selectivity over related GPCRs, and brain exposure. Preclinical studies demonstrated that BI 414 has acceptable in vivo efficacy in animal models of obesity[1][2].

Targets

MCHR1 (Melanin-concentrating hormone receptor 1)

Beyond the preview

Go deeper on BI 414.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 414.

Explore the full profile